Pro Feature
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moCompany
R-Pharm US
NJ - Princeton
SORINE (sotalol hydrochloride) by R-Pharm US is 12. Approved for documented, life-threatening ventricular arrhythmias, such. First approved in 2001.
Drug data last refreshed 18h ago
12.1 Mechanism of Action Sotalol has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. The two isomers of sotalol have similar Class III antiarrhythmic effects, while the l-isomer…
Worked on SORINE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
'Inner Ear Support' Oral Capsule in Patients With Sudden Sensorineural Hearing Loss
Intra-Tympanic Steroid With PRP Combination in Sensorineural Hearing Loss and Tinnitus.
Efficacy and Safety of AC102 Compared to Steroids in Adults With Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL)
Efficacy of SENS 401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss
OSA and Sudden Sensorineural Hearing Loss
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo